Synthesis of deuterium-labeled (3R, 5S)-fluvastatin and (3S, 5R)-fluvastatin
- 13 Downloads
In order to comprehensively understanding the metabolism process of fluvastatin, the stable isotope-labeled (3R, 5S)-fluvastatin and (3S, 5R)-fluvastatin were required. Both of (3R, 5S)-fluvastatin and (3S, 5R)-fluvastatin were synthesized via a seven steps procedure starting from aniline and [2H6] 2-bromopropane. Two versions of deuterium labeled compound revealed over 98% deuterium enrichment, using as an internal standard.
KeywordsDeuterium-labeled Fluvastatin Coronary artery disease Synthesis Enantiomers
Funding was provided by National Natural Science Foundation of China (Grant No. 41472124), PetroChina Innovation Foundation (Grant Nos. 2015D-5006-0210 and 2016D-5007-0702) and Nature Science Foundation of Hubei Province (Grant No. 2016CFB178).
- 1.W. H. O. Report (2018) The top 10 causes of death. http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 24 May 2018
- 5.Kathawala F (1991) HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 11:121–146Google Scholar
- 14.Masuda N, Akasaka I, Ohtawa M et al (1995) Metabolic fate of fluvastatin, an inhibitor of HMG-CoA reductase(2): transfer to the fetus and milk, and absorption, distribution and excretion after consecutive oral administration of [14C] fluvastatin in rats. Drug Metab Pharmacokinet 10:529–546CrossRefGoogle Scholar
- 16.Koftis TV, Panagiotidis T, Soni RR et al (2011) Improved process for the preparation of fluvastatin and salts thereof. WO2010118757A1. Accessed 21 Oct 2010Google Scholar
- 17.Chen K, Hardtmann GE, Lee GT Preparation of olefinic compounds. EP 0244346A2. Accessed 4 Nov 1987Google Scholar
- 18.Fachini M Process for the preparation of fluvastatin sodium salt. US7662848 B2. Accessed 16 Feb 2010Google Scholar
- 21.Kathawala GF Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof. US 4739073. Accessed 19 Apr 1988Google Scholar